Shoreline is developing the next generation of cellular immunotherapies designed to bring safe, effective and affordable treatments to patients in need through intelligently engineered, homogenous and scalable off-the-shelf products enabled by Shoreline’s iNK and iMACs cellular immunotherapy platforms.

Founded in Sweden in 2012, IRRAS is a commercial medical device company, focused on designing, developing, and commercializing innovative solutions that transform fluid management after surgical procedures where drainage is required.

Structure’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry and data integration to develop potentially best-in-class medicines. Its goal is to develop oral small molecule drugs that can deliver biologic-like activity and specificity while overcoming current limitations of biologic and peptide drugs.

Seed Investor / Growth Funding / Crossover

Stork Life Sciences setup Shoreline in July 2020, acquiring the intellectual property and retaining the founding scientists

SLS financed the seed round and subsequently completed a Series A round, receiving financing from key biotech investors

In June 2021, as part of the Series A round, Dr. Xanthopoulos negotiated strategic agreements with both Kite and BeiGene with a significant combined upfront payment and multi-billion-dollar milestone-based payments.

In September 2021, Shoreline initiated a crossover round valuing the company at over USD 500m on a post-money basis.

Seed Investor / Growth Funding / IPO

Mr. Fotiadis co-founded IRRAS in 2013, helping develop a neurosurgeon’s solution to an intractable problem, into the world’s first commercial irrigating intracranial drainage system.

Dr. Xanthopoulos was brought in as CEO in 2016 and helped scale the business and secure regulatory approvals for the device in both the U.S. and Europe, and eventually list the company on the Nordic stock exchange in November 2017. At the time of the listing the company was worth $140 million.

In May 2019, IRRAS acquired Hummingbird, a US-based family of products that help clinicians diagnose and manage patients' intracranial pressure after traumatic brain injury, a subarachnoid hemorrhage, and/or a stroke.

Mr. Fotiadis continues to serve as chairman of the board of directors and Levant Capital has worked with the company to secure several rounds of financing subsequent to the listing, including in a 2022 Rights Issuance.

Seed Investor / Growth Funding / IPO

Based in San-Diego, California, Anadys develops oral, small molecule therapeutics for the potential treatment of hepatitis C virus (HCV) infection

Dr. Xanthopoulos was co-founder and CEO of Anadys.

In early 2015 Anadys signed a global license and co-development agreement with Novartis to develop, manufacture and commercialize some of its drugs.

In October 2011, Roche acquired Anadys for a total cash consideration of approximately $230 million.

Seed Investor / Growth Funding / IPO

Dr. Xanthopoulos served as President and CEO of Regulus Therapeutics Inc. from its inception in 2007 until June 2015.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs.

In April 2008, Regulus entered into a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics with GSK.

In June 2010, Regulus entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics with Sanofi.

In August 2012, Regulus entered into a strategic alliance out-licensing 3 microRNA targets to AstraZeneca to treat cardiovascular and metabolic diseases.

In October 2012, as part of the alliance, AstraZeneca made a concurrent private placement into Regulus at the time of Regulus’ IPO

Growth Funding / Merger / Strategic Sale

LDO is a provider of specialty biological active ingredients for pharmaceutical products. The company was acquired in 2011 at a valuation of EUR 15 million

Over a 9-year period, LDO experienced a growth in revenue of 2.5x and growth in EBITDA of 9x.

SLS led a transaction in 2020 where LDO was acquired by a strategic partner.

A significant portion of the proceeds was reinvested in Opocrin with a 5-year put/call structure at a fixed EBITDA multiple.

At exit in 2022, the shareholders of LDO realized a return multiple of 10x over the investment period.

Mr. Fotiadis served as chairman of the board of LDO and was a member of Opocrin’s board until exiting the investment, contributing significantly to the group’s direction.